Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Headache in Multiple Sclerosis - Pharmacological Aspects

Author(s): Marcel Gebhardt*, Peter Kropp, Frank Hoffmann and Uwe K. Zettl

Volume 28, Issue 6, 2022

Published on: 22 September, 2021

Page: [445 - 453] Pages: 9

DOI: 10.2174/1381612827666210922114100

Price: $65

Abstract

For decades, the headache was not considered a typical symptom of multiple sclerosis (MS) and was construed as a “red flag” for important differential diagnoses such as cerebral vasculitis. Meanwhile, several studies have demonstrated an increased prevalence of headaches in MS compared to the general population. This is due to the heterogeneity of headache genesis with frequent occurrence of both primary and secondary headaches in MS. On the one hand, MS and migraine are often comorbid. On the other hand, secondary headaches frequently occur, especially in the course of MS relapses. These are often migraine-like headaches caused by inflammation, which can improve as a result of MS-specific therapy. Headaches are particularly common in the early stages of chronic inflammatory CNS disease, where inflammatory activity is the greatest. In addition, headaches can also occur as a side effect of disease-modifying drugs (DMDs). Headache can occur with most DMDs and is most frequently described with interferon-beta therapy. The aim of this work is to present the prevalence of headaches and describe the heterogeneity of possible causes of headaches in MS. In addition, important therapeutic aspects in the treatment of MS patients, in general, will be presented as well as different approaches to the treatment of headaches in MS depending on the etiological classification.

Keywords: Clinically isolated syndrome, headache, migraine, multiple sclerosis, disease-modifying drugs, 5 KWs.

« Previous Next »
[1]
Skierlo S, Rommer PS, Zettl UK. Symptomatic treatment in multiple sclerosis-interim analysis of a nationwide registry. Acta Neurol Scand 2017; 135(4): 394-9.
[http://dx.doi.org/10.1111/ane.12612] [PMID: 27283842]
[2]
Cossburn M, Ingram G, Hirst C, Ben-Shlomo Y, Pickersgill TP, Robertson NP. Age at onset as a determinant of presenting phenotype and initial relapse recovery in multiple sclerosis. Mult Scler 2012; 18(1): 45-54.
[http://dx.doi.org/10.1177/1352458511417479] [PMID: 21865412]
[3]
Kalincik T, Buzzard K, Jokubaitis V, et al. Risk of relapse phenotype recurrence in multiple sclerosis. Mult Scler 2014; 20(11): 1511-22.
[http://dx.doi.org/10.1177/1352458514528762] [PMID: 24777276]
[4]
Stuke K, Flachenecker P, Zettl UK, et al. Symptomatology of MS: results from the German MS Registry. J Neurol 2009; 256(11): 1932-5.
[http://dx.doi.org/10.1007/s00415-009-5257-5] [PMID: 19629565]
[5]
Rommer PS, Eichstädt K, Ellenberger D, et al. Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry. Mult Scler 2018; 1352458518799580
[http://dx.doi.org/10.1177/1352458518799580] [PMID: 30230952]
[6]
Stenager E, Knudsen L, Jensen K. Acute and chronic pain syndromes in multiple sclerosis. A 5-year follow-up study. Ital J Neurol Sci 1995; 16(9): 629-32.
[http://dx.doi.org/10.1007/BF02230913] [PMID: 8838789]
[7]
Ellenberger D, Flachenecker P, Haas J, et al. Is benign MS really benign? What a meaningful classification beyond the EDSS must take into consideration. Mult Scler Relat Disord 2020; 46: 102485.
[http://dx.doi.org/10.1016/j.msard.2020.102485] [PMID: 32980646]
[8]
Ellenberger D, Flachenecker P, Fneish F, et al. Aggressive multiple sclerosis: a matter of measurement and timing. Brain 2020; 143(11): e97.
[http://dx.doi.org/10.1093/brain/awaa306] [PMID: 33175163]
[9]
Bonduelle M, Albaranes R. Étude statistique de 145 case de sclérose en plaque. Sem Hop Paris 1962; 68: 3762-73.
[PMID: 13968749]
[10]
Poser CM, Presthus J, Horsda O. Clinical characteristics of autopsy-proved multiple sclerosis. Neurology 1966; 16: 791-8.
[http://dx.doi.org/10.1212/WNL.16.8.791]
[11]
McALPINE D, Compston N. Some aspects of the natural history of disseminated sclerosis. Q J Med 1952; 21(82): 135-67.
[PMID: 14941968]
[12]
Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008; 14(9): 1157-74.
[http://dx.doi.org/10.1177/1352458508096878] [PMID: 18805839]
[13]
Klotz L, Gold R, Hemmer B, et al. Diagnosis of multiple sclerosis 2010 revision of the McDonald criteria. Nervenarzt 2011; 82(10): 1302-9.
[http://dx.doi.org/10.1007/s00115-011-3283-x] [PMID: 21681517]
[14]
Kister I, Caminero AB, Monteith TS, et al. Migraine is comorbid with multiple sclerosis and associated with a more symptomatic MS course. J Headache Pain 2010; 11(5): 417-25.
[http://dx.doi.org/10.1007/s10194-010-0237-9] [PMID: 20625916]
[15]
Villani V, Prosperini L, Ciuffoli A, et al. Primary headache and multiple sclerosis: preliminary results of a prospective study. Neurol Sci 2008; 29(Suppl. 1): S146-8.
[http://dx.doi.org/10.1007/s10072-008-0908-3] [PMID: 18545918]
[16]
D’Amico D, La Mantia L, Rigamonti A, et al. Prevalence of primary headaches in people with multiple sclerosis. Cephalalgia 2004; 24(11): 980-4.
[http://dx.doi.org/10.1111/j.1468-2982.2004.00790.x] [PMID: 15482362]
[17]
Nicoletti A, Patti F, Lo Fermo S, et al. Headache and multiple sclerosis: a population-based case-control study in Catania, Sicily. Cephalalgia 2008; 28(11): 1163-9.
[http://dx.doi.org/10.1111/j.1468-2982.2008.01662.x] [PMID: 18727645]
[18]
Putzki N, Pfriem A, Limmroth V, et al. Prevalence of migraine, tension-type headache and trigeminal neuralgia in multiple sclerosis. Eur J Neurol 2009; 16(2): 262-7.
[http://dx.doi.org/10.1111/j.1468-1331.2008.02406.x] [PMID: 19138330]
[19]
Möhrke J, Kropp P, Zettl UK. Headaches in multiple sclerosis patients might imply an inflammatorial process. PLoS One 2013; 8(8): e69570.
[http://dx.doi.org/10.1371/journal.pone.0069570] [PMID: 23940524]
[20]
Vacca G, Marano E, Brescia Morra V, et al. Multiple sclerosis and headache co-morbidity. A case-control study. Neurol Sci 2007; 28(3): 133-5.
[http://dx.doi.org/10.1007/s10072-007-0805-1] [PMID: 17603764]
[21]
Moisset X, Ouchchane L, Guy N, Bayle DJ, Dallel R, Clavelou P. Migraine headaches and pain with neuropathic characteristics: comorbid conditions in patients with multiple sclerosis. Pain 2013; 154(12): 2691-9.
[http://dx.doi.org/10.1016/j.pain.2013.07.050] [PMID: 23911697]
[22]
Beckmann Y, Türe S. Headache characteristics in multiple sclerosis. Mult Scler Relat Disord 2019; 27: 112-6.
[http://dx.doi.org/10.1016/j.msard.2018.09.022] [PMID: 30368222]
[23]
Gebhardt M, Kropp P, Jürgens TP, Hoffmann F, Zettl UK. Headache in the first manifestation of Multiple Sclerosis - Prospective, multicenter study. Brain Behav 2017; 7(12): e00852.
[http://dx.doi.org/10.1002/brb3.852] [PMID: 29299379]
[24]
Gebhardt M, Kropp P, Hoffmann F, Zettl UK. Kopfschmerzen bei Multipler Sklerose [Headache in multiple sclerosis]. Nervenarzt 2020; 91(10): 926-35.
[http://dx.doi.org/10.1007/s00115-020-00959-0]
[25]
Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight project. J Headache Pain 2010; 11(4): 289-99.
[http://dx.doi.org/10.1007/s10194-010-0217-0] [PMID: 20473702]
[26]
Wang L, Zhang J, Deng Z-R, Zu M-D, Wang Y. The epidemiology of primary headaches in patients with multiple sclerosis. Brain Behav 2021; 11(1): e01830.
[http://dx.doi.org/10.1002/brb3.1830] [PMID: 33295123]
[27]
Yoon MS, Katsarava Z, Obermann M, et al. Prevalence of primary headaches in Germany: results of the German Headache Consortium Study. J Headache Pain 2012; 13(3): 215-23.
[http://dx.doi.org/10.1007/s10194-012-0425-x] [PMID: 22395638]
[28]
Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007; 68(5): 343-9.
[http://dx.doi.org/10.1212/01.wnl.0000252808.97649.21] [PMID: 17261680]
[29]
Stovner Lj, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007; 27(3): 193-210.
[http://dx.doi.org/10.1111/j.1468-2982.2007.01288.x] [PMID: 17381554]
[30]
Burch RC, Loder S, Loder E, Smitherman TA. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache 2015; 55(1): 21-34.
[http://dx.doi.org/10.1111/head.12482] [PMID: 25600719]
[31]
Mirmosayyeb O, Barzegar M, Nehzat N, Shaygannejad V, Sahraian MA, Ghajarzadeh M. The prevalence of migraine in multiple sclerosis (MS): A systematic review and meta-analysis. J Clin Neurosci 2020; 79: 33-8.
[http://dx.doi.org/10.1016/j.jocn.2020.06.021] [PMID: 33070914]
[32]
Ergün U, Özer G, Sekercan S, et al. Headache in the different phases of relapsing-remitting multiple sclerosis. Neurologist 2009; 15: 212-6.
[http://dx.doi.org/10.1097/NRL.0b013e3181906fc9] [PMID: 19590381]
[33]
Klein M, Woehrl B, Zeller G, Straube A. Stabbing headache as a sign of relapses in multiple sclerosis. Headache 2013; 53(7): 1159-61.
[http://dx.doi.org/10.1111/head.12138] [PMID: 23808488]
[34]
Gebhardt M, Kropp P, Hoffmann F, Zettl UK. Headache in the course of multiple sclerosis: a prospective study. J Neural Transm (Vienna) 2019; 126(2): 131-9.
[http://dx.doi.org/10.1007/s00702-018-1959-0] [PMID: 30506270]
[35]
Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132(Pt 5): 1175-89.
[http://dx.doi.org/10.1093/brain/awp070] [PMID: 19339255]
[36]
Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol 2015; 14(2): 183-93.
[http://dx.doi.org/10.1016/S1474-4422(14)70256-X] [PMID: 25772897]
[37]
Lassmann H. Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front Immunol 2019; 9: 3116.
[http://dx.doi.org/10.3389/fimmu.2018.03116] [PMID: 30687321]
[38]
Gebhardt M, Kropp P, Hoffmann F, Zettl UK. Headache at the time of first symptom manifestation of multiple sclerosis: A prospective, longitudinal study. Eur Neurol 2018; 80(3-4): 115-20.
[http://dx.doi.org/10.1159/000494092] [PMID: 30368493]
[39]
Silberstein S, Loder E, Diamond S, Reed ML, Bigal ME, Lipton RB. Probable migraine in the United States: results of the American Migraine Prevalence and Prevention (AMPP) study. Cephalalgia 2007; 27(3): 220-9.
[http://dx.doi.org/10.1111/j.1468-2982.2006.01275.x] [PMID: 17263769]
[40]
Lantéri-Minet M, Valade D, Géraud G, Chautard MH, Lucas C. Migraine and probable migraine--results of FRAMIG 3, a French nationwide survey carried out according to the 2004 IHS classification. Cephalalgia 2005; 25(12): 1146-58.
[http://dx.doi.org/10.1111/j.1468-2982.2005.00977.x] [PMID: 16305603]
[41]
Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007; 130(Pt 4): 1089-104.
[PMID: 17438020]
[42]
Levy D. Migraine pain, meningeal inflammation, and mast cells. Curr Pain Headache Rep 2009; 13(3): 237-40.
[http://dx.doi.org/10.1007/s11916-009-0040-y] [PMID: 19457286]
[43]
Ashina M, Dodick D, Goadsby PJ, et al. Erenumab (AMG 334) in episodic migraine: interim analysis of an ongoing open-label study. 2017; 89: 1237-43.
[44]
Dodick DW, Ashina M, Brandes JL, et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 2018; 38(6): 1026-37.
[http://dx.doi.org/10.1177/0333102418759786] [PMID: 29471679]
[45]
Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 2017; 16(6): 425-34.
[http://dx.doi.org/10.1016/S1474-4422(17)30083-2] [PMID: 28460892]
[46]
Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med 2017; 377(22): 2123-32.
[http://dx.doi.org/10.1056/NEJMoa1705848] [PMID: 29171821]
[47]
Russell FA, King R, Smillie SJ, Kodji X, Brain SD. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev 2014; 94(4): 1099-142.
[http://dx.doi.org/10.1152/physrev.00034.2013] [PMID: 25287861]
[48]
Bracci-Laudiero L, Aloe L, Buanne P, et al. NGF modulates CGRP synthesis in human B-lymphocytes: a possible anti-inflammatory action of NGF? J Neuroimmunol 2002; 123(1-2): 58-65.
[http://dx.doi.org/10.1016/S0165-5728(01)00475-1] [PMID: 11880150]
[49]
Toosy AT, Mason DF, Miller DH. Optic neuritis. Lancet Neurol 2014; 13(1): 83-99.
[http://dx.doi.org/10.1016/S1474-4422(13)70259-X] [PMID: 24331795]
[50]
Martinelli Boneschi F, Colombo B, Annovazzi P, et al. Lifetime and actual prevalence of pain and headache in multiple sclerosis. Mult Scler 2008; 14(4): 514-21.
[http://dx.doi.org/10.1177/1352458507085551] [PMID: 18562506]
[51]
Moulin DE, Foley KM, Ebers GC. Pain syndromes in multiple sclerosis. Neurology 1988; 38(12): 1830-4.
[http://dx.doi.org/10.1212/WNL.38.12.1830] [PMID: 2973568]
[52]
Solaro C, Brichetto G, Amato MP, et al. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology 2004; 63(5): 919-21.
[http://dx.doi.org/10.1212/01.WNL.0000137047.85868.D6] [PMID: 15365151]
[53]
MacDonald BK, Cockerell OC, Sander JW, Shorvon SD. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 2000; 123(Pt 4): 665-76.
[http://dx.doi.org/10.1093/brain/123.4.665] [PMID: 10733998]
[54]
Di Stefano G, Maarbjerg S, Truini A. Trigeminal neuralgia secondary to multiple sclerosis: from the clinical picture to the treatment options. J Headache Pain 2019; 20(1): 20.
[http://dx.doi.org/10.1186/s10194-019-0969-0] [PMID: 30782116]
[55]
Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003; 61(4): 551-4.
[http://dx.doi.org/10.1212/01.WNL.0000078885.05053.7D] [PMID: 12939437]
[56]
Yong VW, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998; 51(3): 682-9.
[http://dx.doi.org/10.1212/WNL.51.3.682] [PMID: 9748010]
[57]
Schubert RD, Hu Y, Kumar G, et al. IFN-β treatment requires B cells for efficacy in neuroautoimmunity. J Immunol 2015; 194(5): 2110-6.
[http://dx.doi.org/10.4049/jimmunol.1402029] [PMID: 25646307]
[58]
Filippini G, Munari L, Incorvaia B, et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 2003; 361(9357): 545-52.
[http://dx.doi.org/10.1016/S0140-6736(03)12512-3] [PMID: 12598138]
[59]
Pöllmann W, Erasmus LP, Feneberg W, Then Bergh F, Straube A. Interferon beta but not glatiramer acetate therapy aggravates headaches in MS. Neurology 2002; 59(4): 636-9.
[http://dx.doi.org/10.1212/WNL.59.4.636] [PMID: 12196668]
[60]
La Mantia L. Headache and multiple sclerosis: clinical and therapeutic correlations. Neurol Sci 2009; 30(Suppl. 1): S23-6.
[http://dx.doi.org/10.1007/s10072-009-0053-7] [PMID: 19415421]
[61]
Patti F, Nicoletti A, Pappalardo A, et al. Frequency and severity of headache is worsened by interferon beta therapy in patients with multiple sclerosis. Acta Neurol Scand 2012; 125(2): 91-5.
[http://dx.doi.org/10.1111/j.1600-0404.2011.01532.x] [PMID: 21649611]
[62]
Nakatsuji Y, Nakano M, Moriya M, et al. Beneficial effect of interferon-beta treatment in patients with multiple sclerosis is associated with transient increase in serum IL-6 level in response to interferon-beta injection. Cytokine 2006; 36(1-2): 69-74.
[http://dx.doi.org/10.1016/j.cyto.2006.10.013] [PMID: 17161613]
[63]
Bischof A, Sprenger T. Interferon beta-associated recurrence of painful trigeminal neuropathy attributed to a multiple sclerosis plaque. J Headache Pain 2014; 15: 21.
[http://dx.doi.org/10.1186/1129-2377-15-21] [PMID: 24742132]
[64]
Arnon R, Aharoni R. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci USA 2004; 101(Suppl. 2): 14593-8.
[http://dx.doi.org/10.1073/pnas.0404887101] [PMID: 15371592]
[65]
Tennakoon DK, Mehta RS, Ortega SB, Bhoj V, Racke MK, Karandikar NJ. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J Immunol 2006; 176(11): 7119-29.
[http://dx.doi.org/10.4049/jimmunol.176.11.7119] [PMID: 16709875]
[66]
Pul R, Morbiducci F, Škuljec J, et al. Glatiramer acetate increases phagocytic activity of human monocytes in vitro and in multiple sclerosis patients. PLoS One 2012; 7(12): e51867.
[http://dx.doi.org/10.1371/journal.pone.0051867] [PMID: 23284793]
[67]
Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356(6364): 63-6.
[http://dx.doi.org/10.1038/356063a0] [PMID: 1538783]
[68]
Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354(9): 899-910.
[http://dx.doi.org/10.1056/NEJMoa044397] [PMID: 16510744]
[69]
Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348(1): 15-23.
[http://dx.doi.org/10.1056/NEJMoa020696] [PMID: 12510038]
[70]
Villani V, De Giglio L, Sette G, Pozzilli C, Salvetti M, Prosperini L. Determinants of the severity of comorbid migraine in multiple sclerosis. Neurol Sci 2012; 33(6): 1345-53.
[http://dx.doi.org/10.1007/s10072-012-1119-5] [PMID: 22644131]
[71]
Havrdova E, Horakova D, Kovarova I. Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Ther Adv Neurol Disord 2015; 8(1): 31-45.
[http://dx.doi.org/10.1177/1756285614563522] [PMID: 25584072]
[72]
Klotz L, Meuth SG, Kieseier B, Wiendl H. Alemtuzumab bei schubförmig-remittierender multipler Sklerose. Ergebnisse von 2 randomisierten kontrollierten Phase-III-Studien [Alemtuzumab for relapsing-remitting multiple sclerosis. Results of two randomized controlled phase III studies]. Nervenarzt 2013; 84(8): 984-4.
[http://dx.doi.org/10.1007/s00115-013-3814-8]
[73]
Havrdova E, Arnold DL, Cohen JA, et al. Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. Neurology 2017; 89(11): 1107-16. [Erratum in: Neurology. 2018 Apr 17;90]. [16]. [:755. PMID: 28835401; PMCID: PMC5595278].
[http://dx.doi.org/10.1212/WNL.0000000000004313] [PMID: 28835401]
[74]
Pape K, Zipp F, Bittner S. Neues aus der Immuntherapie bei Multipler Sklerose [New aspects of immunotherapy in multiple sclerosis]. Nervenarzt 2018; 89(12): 1365-70.
[http://dx.doi.org/10.1007/s00115-018-0542-0]
[75]
Sorensen PS, Blinkenberg M. The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Ther Adv Neurol Disord 2016; 9(1): 44-52.
[http://dx.doi.org/10.1177/1756285615601933] [PMID: 26788130]
[76]
Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 2017; 376(3): 221-34.
[http://dx.doi.org/10.1056/NEJMoa1601277] [PMID: 28002679]
[77]
Stahnke AM, Holt KM. Ocrelizumab: a new B-cell therapy for relapsing remitting and primary progressive multiple sclerosis. Ann Pharmacother 2018; 52(5): 473-83.
[http://dx.doi.org/10.1177/1060028017747635] [PMID: 29232960]
[78]
Wolinsky JS, Arnold DL, Brochet B, et al. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2020; 19(12): 998-1009. [Erratum in: Lancet Neurol. 2020 Nov 17; PMID: 33129442].
[http://dx.doi.org/10.1016/S1474-4422(20)30342-2] [PMID: 33129442]
[79]
Hauser SL, Kappos L, Arnold DL, et al. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology 2020; 95(13): e1854-67.
[http://dx.doi.org/10.1212/WNL.0000000000010376] [PMID: 32690791]
[80]
Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761053lbl.pdf#page=17
[81]
Willis MA, Cohen JA. Fingolimod therapy for multiple sclerosis. Semin Neurol 2013; 33(1): 37-44.
[http://dx.doi.org/10.1055/s-0033-1343794] [PMID: 23709211]
[82]
Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362(5): 387-401.
[http://dx.doi.org/10.1056/NEJMoa0909494] [PMID: 20089952]
[83]
Fragoso YD, Adoni T, Gomes S, et al. Persistent headache in patients with multiple sclerosis starting treatment with fingolimod. Headache 2015; 55(4): 578-9.
[http://dx.doi.org/10.1111/head.12526] [PMID: 25754576]
[84]
Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 2018; 391(10127): 1263-73.
[http://dx.doi.org/10.1016/S0140-6736(18)30475-6] [PMID: 29576505]
[85]
Al-Salama ZT. Siponimod: First global approval. Drugs 2019; 79(9): 1009-15.
[http://dx.doi.org/10.1007/s40265-019-01140-x] [PMID: 31144287]
[86]
Tran JQ, Hartung JP, Peach RJ, et al. Results from the first-in-human study with ozanimod, a novel, selective sphingosine-1-phosphate receptor modulator. J Clin Pharmacol 2017; 57(8): 988-96.
[http://dx.doi.org/10.1002/jcph.887] [PMID: 28398597]
[87]
Cohen JA, Arnold DL, Comi G, et al. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2016; 15(4): 373-81.
[http://dx.doi.org/10.1016/S1474-4422(16)00018-1] [PMID: 26879276]
[88]
European Medicines Agency. Zeposia. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/zeposia
[89]
Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs 2014; 74(6): 659-74.
[http://dx.doi.org/10.1007/s40265-014-0212-x] [PMID: 24740824]
[90]
Miller AE, Wolinsky JS, Kappos L, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13(10): 977-86.
[http://dx.doi.org/10.1016/S1474-4422(14)70191-7] [PMID: 25192851]
[91]
Miller AE. Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis. Clin Ther 2015; 37(10): 2366-80.
[http://dx.doi.org/10.1016/j.clinthera.2015.08.003] [PMID: 26365096]
[92]
O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365(14): 1293-303.
[http://dx.doi.org/10.1056/NEJMoa1014656] [PMID: 21991951]
[93]
Linker RA, Gold R. Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects. Curr Neurol Neurosci Rep 2013; 13(11): 394.
[http://dx.doi.org/10.1007/s11910-013-0394-8] [PMID: 24061646]
[94]
European Medicine Agency. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tecfidera
[95]
Ochi H, Niino M, Onizuka Y, et al. 72-week safety and tolerability of dimethyl fumarate in Japanese patients with relapsing-remitting multiple sclerosis: Analysis of the randomised, double blind, placebo-controlled, phase III APEX study and its open-label extension. Adv Ther 2018; 35(10): 1598-611.
[http://dx.doi.org/10.1007/s12325-018-0788-8] [PMID: 30206820]
[96]
Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 372(9648): 1463-72.
[http://dx.doi.org/10.1016/S0140-6736(08)61619-0] [PMID: 18970976]
[97]
Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol 2011; 34(1): 28-35.
[http://dx.doi.org/10.1097/WNF.0b013e318204cd90] [PMID: 21242742]
[98]
Drugs at FDA. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022561s000lbl.pdf#page=29
[99]
European Medicines Agency. Mavenclad. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/mavenclad
[100]
Giovannoni G, Soelberg Sorensen P, Cook S, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Mult Scler 2018; 24(12): 1594-604.
[http://dx.doi.org/10.1177/1352458517727603] [PMID: 28870107]
[101]
Rommer PS, Zettl UK. Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients. Expert Opin Pharmacother 2018; 19(5): 483-98.
[http://dx.doi.org/10.1080/14656566.2018.1446944] [PMID: 29528247]
[102]
Winkelmann A, Loebermann M, Reisinger EC, Hartung HP, Zettl UK. Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol 2016; 12(4): 217-33.
[http://dx.doi.org/10.1038/nrneurol.2016.21] [PMID: 26943779]
[103]
Moiola L, Rommer PS, Zettl UK. Prevention and management of adverse effects of disease modifying treatments in multiple sclerosis. Curr Opin Neurol 2020; 33(3): 286-94.
[http://dx.doi.org/10.1097/WCO.0000000000000824] [PMID: 32374570]
[104]
Frahm N, Hecker M, Zettl UK. Polypharmacy in outpatients with relapsing-remitting multiple sclerosis: a single-center study. PLoS ONE 2019; 14(1): e211120.
[105]
Frahm N, Hecker M, Zettl UK. Polypharmacy among patients with multiple sclerosis: a qualitative systematic review. Expert Opin Drug Saf 2020; 19(2): 139-45.
[http://dx.doi.org/10.1080/14740338.2020.1720646] [PMID: 31965869]
[106]
Marrie RA. Comorbidity in multiple sclerosis: implications for patient care. Nat Rev Neurol 2017; 13(6): 375-82.
[http://dx.doi.org/10.1038/nrneurol.2017.33] [PMID: 28303911]
[107]
Kowalec K, McKay KA, Patten SB, et al. CIHR Team in Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS) (2017) Comorbidity increases the risk of relapse in multiple sclerosis: a prospective study. Neurology 2017; 89(24): 2455-61.
[108]
Ng HS, Zhu F, Kingwell E, et al. Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting. Expert Rev Neurother 2021; 21(1): 131-40.
[http://dx.doi.org/10.1080/14737175.2021.1847085] [PMID: 33146570]
[109]
Marrie RA, Reider N, Cohen J, et al. A systematic review of the incidence and prevalence of cancer in multiple sclerosis. Mult Scler 2015; 21(3): 294-304.
[http://dx.doi.org/10.1177/1352458514564489] [PMID: 25533302]
[110]
Marrie RA, Maxwell C, Mahar A, et al. Cancer incidence and mortality rates in multiple sclerosis: A matched cohort study. Neurology 2021; 96(4): e501-12.
[http://dx.doi.org/10.1212/WNL.0000000000011219] [PMID: 33239364]
[111]
Apel-Neu A, Zettl UK. Complementary and alternative medicine in multiple sclerosis. J Neurol 2008; 255(Suppl. 6): 82-6.
[http://dx.doi.org/10.1007/s00415-008-6015-9] [PMID: 19300965]
[112]
Rommer PS, König N, Sühnel A, Zettl UK. Coping behavior in multiple sclerosis-complementary and alternative medicine: A cross-sectional study. CNS Neurosci Ther 2018; 24(9): 784-9.
[http://dx.doi.org/10.1111/cns.12857] [PMID: 29635832]
[113]
Foley PL, Vesterinen HM, Laird BJ, et al. Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis. Pain 2013; 154(5): 632-42.
[http://dx.doi.org/10.1016/j.pain.2012.12.002] [PMID: 23318126]
[114]
O’Connor AB, Schwid SR, Herrmann DN, Markman JD, Dworkin RH. Pain associated with multiple sclerosis: systematic review and proposed classification. Pain 2008; 137(1): 96-111.
[http://dx.doi.org/10.1016/j.pain.2007.08.024] [PMID: 17928147]
[115]
Hemmett L, Holmes J, Barnes M, Russell N. What drives quality of life in multiple sclerosis? QJM 2004; 97(10): 671-6.
[http://dx.doi.org/10.1093/qjmed/hch105] [PMID: 15367738]
[116]
Aboud T, Schuster NM. Pain management in multiple sclerosis: A review of available treatment options. Curr Treat Options Neurol 2019; 21(12): 62.
[http://dx.doi.org/10.1007/s11940-019-0601-2] [PMID: 31773455]
[117]
Gold R, Oreja-Guevara C. Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines. Expert Rev Neurother 2013; 13(12)(Suppl.): 55-9.
[http://dx.doi.org/10.1586/14737175.2013.865880] [PMID: 24289845]
[118]
Henze T, Rieckmann P, Toyka KV. Symptomatic treatment of multiple sclerosis. Eur Neurol 2006; 56(2): 78-105.
[http://dx.doi.org/10.1159/000095699] [PMID: 16966832]
[119]
Mariotti P, Nociti V, Cianfoni A, et al. Migraine-like headache and status migrainosus as attacks of multiple sclerosis in a child. Pediatrics 2010; 126(2): e459-64.
[http://dx.doi.org/10.1542/peds.2009-2098] [PMID: 20603252]
[120]
Mariotti P, Nociti V, Stefanini MC, et al. Chronic migraine-like headache caused by a demyelinating lesion in the brain stem. Pain Med 2012; 13(4): 610-2.
[http://dx.doi.org/10.1111/j.1526-4637.2012.01344.x] [PMID: 22390362]
[121]
Alroughani R, Ahmed SF, Khan R, Al-Hashel J. Status migrainosus as an initial presentation of multiple sclerosis. Springerplus 2015; 4: 28.
[http://dx.doi.org/10.1186/s40064-015-0818-9] [PMID: 25646151]
[122]
González-Quintanilla V, Oterino A, Toriello M, et al. Cluster-tic syndrome as the initial manifestation of multiple sclerosis. J Headache Pain 2012; 13(5): 425-9.
[http://dx.doi.org/10.1007/s10194-012-0449-2] [PMID: 22543446]
[123]
Mijajlović MD, Aleksić VM, Covičković Šternić NM. Cluster headache as a first manifestation of multiple sclerosis: case report and literature review. Neuropsychiatr Dis Treat 2014; 10: 2269-74.
[http://dx.doi.org/10.2147/NDT.S73491] [PMID: 25473291]
[124]
Filippini G, Brusaferri F, Sibley WA, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000; (4): CD001331.
[http://dx.doi.org/10.1002/14651858.CD001331] [PMID: 11034713]
[125]
Ross AP, Ben-Zacharia A, Harris C, Smrtka J. Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormone. Front Neurol 2013; 4: 21.
[http://dx.doi.org/10.3389/fneur.2013.00021] [PMID: 23482896]
[126]
Müller B, Baum A, Holzhausen M, et al. The Rostock Headache Questionnaire (“Rokoko”)--validation of a tool to screen and to qualify primary headaches. Fortschr Neurol Psychiatr 2014; 82(3): 145-8.
[PMID: 24615585]
[127]
Villani V, Prosperini L, Pozzilli C, Salvetti M, Ciuffoli A, Sette G. The use of ID migraine™ questionnaire in patients with multiple sclerosis. Neurol Sci 2011; 32(2): 269-73.
[http://dx.doi.org/10.1007/s10072-010-0443-x] [PMID: 21069404]
[128]
Buch D, Chabriat H. Lamotrigine in the prevention of migraine with aura: A narrative review. Headache 2019; 59(8): 1187-97.
[http://dx.doi.org/10.1111/head.13615] [PMID: 31468532]
[129]
Goh KK, Chen CH, Chiu YH, Lu ML. Lamotrigine augmentation in treatment-resistant unipolar depression: A comprehensive meta-analysis of efficacy and safety. J Psychopharmacol 2019; 33(6): 700-13.
[http://dx.doi.org/10.1177/0269881119844199] [PMID: 31081449]
[130]
Katsiari CG, Vikelis M, Paraskevopoulou ES, Sfikakis PP, Mitsikostas DD. Headache in systemic lupus erythematosus vs multiple sclerosis: a prospective comparative study. Headache 2011; 51(9): 1398-407.
[http://dx.doi.org/10.1111/j.1526-4610.2011.01962.x] [PMID: 21797859]
[131]
Gelfand AA, Goadsby PJ. A neurologist’s guide to acute migraine therapy in the emergency room. Neurohospitalist 2012; 2(2): 51-9.
[http://dx.doi.org/10.1177/1941874412439583] [PMID: 23936605]
[132]
Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78(17): 1337-45. [Erratum in: Neurology. 2013 Feb 26;80]. [9]. [:871. PMID: 22529202; PMCID: PMC3335452].
[http://dx.doi.org/10.1212/WNL.0b013e3182535d20] [PMID: 22529202]
[133]
Cady RK, Banks J, Jones BA, Campbell J. Postmarketing migraine survey of frovatriptan: effectiveness and tolerability vs previous triptans, NSAIDs or a combination. Curr Med Res Opin 2009; 25(11): 2711-21.
[http://dx.doi.org/10.1185/03007990903285449] [PMID: 19778164]
[134]
Smith T, Blumenthal H, Diamond M, et al. Sumatriptan/Naproxen sodium for migraine: efficacy, health related quality of life, and satisfaction outcomes. Headache 2007; 47(5): 683-92.
[http://dx.doi.org/10.1111/j.1526-4610.2007.00790.x] [PMID: 17501849]
[135]
Villani V, Prosperini L, De Giglio L, Pozzilli C, Salvetti M, Sette G. The impact of interferon beta and natalizumab on comorbid migraine in multiple sclerosis. Headache 2012; 52(7): 1130-5.
[http://dx.doi.org/10.1111/j.1526-4610.2012.02146.x] [PMID: 22486199]
[136]
Villani V, Prosperini L, Pozzilli C, Salvetti M, Sette G. Quality of life of multiple sclerosis patients with comorbid migraine. Neurol Sci 2011; 32(Suppl. 1): S149-51.
[http://dx.doi.org/10.1007/s10072-011-0519-2] [PMID: 21533733]
[137]
Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55(6): 754-62. [Erratum in: Neurology 2000 Jan 9;56]. [1]. [:142. PMID: 10993991. Practice guideline update summary: Acute treatment of migraine in children and adolescents].
[http://dx.doi.org/10.1212/WNL.55.6.754] [PMID: 10993991]
[138]
Oskoui M, Pringsheim T, Billinghurst L, et al. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2019; 93(11): 500-9. [Erratum in: Neurology. 2020 Jan 7;94]. [1]. [:50. PMID: 31413170; PMCID: PMC6746206].
[http://dx.doi.org/10.1212/WNL.0000000000008105] [PMID: 31413170]
[139]
Gelfand AA, Gelfand JM, Goadsby PJ. Migraine and multiple sclerosis: Epidemiology and approach to treatment. Mult Scler Relat Disord 2013; 2(2): 73-9.
[http://dx.doi.org/10.1016/j.msard.2012.10.003] [PMID: 25877626]
[140]
Bell DSH, Goncalves E. Diabetogenic effects of cardioprotective drugs. Diabetes Obes Metab 2021; 23(4): 877-85.
[http://dx.doi.org/10.1111/dom.14295] [PMID: 33319474]
[141]
Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 1995; 45(4): 712-7.
[http://dx.doi.org/10.1212/WNL.45.4.712] [PMID: 7723960]
[142]
Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 2011; 60(4): 742-50.
[http://dx.doi.org/10.1016/j.eururo.2011.07.002] [PMID: 21798658]
[143]
Husain F, Pardo G, Rabadi M. Headache and its management in patients with multiple sclerosis. Curr Treat Options Neurol 2018; 20(4): 10.
[http://dx.doi.org/10.1007/s11940-018-0495-4] [PMID: 29574601]

Rights & Permissions Print Cite
Article Metrics
31
1
© 2024 Bentham Science Publishers | Privacy Policy